Activation of the IL-6/JAK/STAT3 pathway has been reported in many tumor types including breast, and additionally elevated serum levels of IL-6 in breast cancer patients have been linked to poor prognosis [39, 40]. This evidence concerns the gene STAT3 and breast carcinoma.